Overview
flowchart TD
companies_landsteiner_scientif["Landsteiner Scientific"]
companies_landsteiner_scientif["Mexican"]
companies_landsteiner_scientif -->|"related to"| companies_landsteiner_scientif
style companies_landsteiner_scientif fill:#81c784,stroke:#333,color:#000
companies_landsteiner_scientif["pharmaceutical"]
companies_landsteiner_scientif -->|"related to"| companies_landsteiner_scientif
style companies_landsteiner_scientif fill:#81c784,stroke:#333,color:#000
companies_landsteiner_scientif["company"]
companies_landsteiner_scientif -->|"related to"| companies_landsteiner_scientif
style companies_landsteiner_scientif fill:#81c784,stroke:#333,color:#000
companies_landsteiner_scientif["headquartered"]
companies_landsteiner_scientif -->|"related to"| companies_landsteiner_scientif
style companies_landsteiner_scientif fill:#81c784,stroke:#333,color:#000
style companies_landsteiner_scientif fill:#4fc3f7,stroke:#333,color:#000
Landsteiner Scientific is a Mexican pharmaceutical company headquartered in Mexico City, dedicated to developing and manufacturing innovative medications for neurodegenerative diseases, cardiovascular disorders, and metabolic conditions. Founded in 2005, Landsteiner Scientific has established itself as a leading Mexican pharmaceutical company focused on bringing novel therapies to the Latin American market.
...Overview
Mermaid diagram (expand to render)
Landsteiner Scientific is a Mexican pharmaceutical company headquartered in Mexico City, dedicated to developing and manufacturing innovative medications for neurodegenerative diseases, cardiovascular disorders, and metabolic conditions. Founded in 2005, Landsteiner Scientific has established itself as a leading Mexican pharmaceutical company focused on bringing novel therapies to the Latin American market.
The company's name honors Karl Landsteiner, the Austrian immunologist who discovered blood groups, reflecting its historical roots in hematology and immunology. Today, Landsteiner Scientific operates across multiple therapeutic areas with a focus on diseases prevalent in the Latin American population["landsteiner"].
Company Profile
| Attribute | Value |
|-----------|-------|
| Headquarters | Mexico City, Mexico |
| Founded | 2005 |
| Focus | CNS, cardiovascular, metabolic diseases |
| Employees | ~500 (as of 2024) |
| Stage | Commercial |
Landsteiner Scientific operates from modern manufacturing facilities in the State of Mexico, with distribution networks throughout Mexico and select Latin American countries. The company maintains research collaborations with leading Mexican universities and international partners.
Therapeutic Focus
Neurodegenerative Diseases
Landsteiner Scientific has established programs in Parkinson's disease and related neurodegenerative conditions:
Parkinson's disease: Development of novel dopamine agonists and COMT inhibitors
Neuroprotection: Compounds targeting mitochondrial dysfunction and oxidative stress
Cognitive enhancement: Programs addressing dementia in Parkinson's disease[@kalia2015]The company recognizes the significant unmet need in Parkinson's treatment in Latin America, where access to novel therapies is limited[schapira2019].
Alzheimer's Disease
Landsteiner offers comprehensive Alzheimer's disease therapies:
- Cholinesterase inhibitors: Donepezil, Rivastigmine, Galantamine
- NMDA antagonist: Memantine
- Combination therapies: Donepezil/Memantine fixed-dose combinations
Cardiovascular Disease
A significant portion of Landsteiner's pipeline focuses on cardiovascular conditions:
Antihypertensives: Novel agents for blood pressure control
Anticoagulants: Next-generation anticoagulation therapies
Lipid-lowering: Statin combinations and novel lipid modifiersLandsteiner Scientific addresses prevalent metabolic conditions:
Diabetes: Oral hypoglycemic agents and combination therapies
Obesity: Weight management solutions
Metabolic syndrome: Integrated approaches to metabolic disordersProduct Portfolio
CNS Products
| Product | Indication | Status |
|---------|------------|--------|
| LST-001 | Parkinson's disease (dopamine agonist) | Approved (Mexico) |
| LST-002 | Parkinson's disease (adjunct therapy) | Phase III |
| LST-003 | Restless legs syndrome | Phase II |
| Donepezil | Alzheimer's disease | Approved |
| Rivastigmine | Alzheimer's disease | Approved |
| Memantine | Alzheimer's disease | Approved |
Cardiovascular Products
| Product | Indication | Status |
|---------|------------|--------|
| LST-CV1 | Hypertension | Approved |
| LST-CV2 | Anticoagulation | Approved |
| LST-CV3 | Hyperlipidemia | Phase III |
| Product | Indication | Status |
|---------|------------|--------|
| LST-M1 | Type 2 diabetes | Approved |
| LST-M2 | Obesity | Approved |
| LST-M3 | Metabolic syndrome | Phase II |
Research and Development
Pipeline Strategy
Landsteiner Scientific employs a multi-pronged R&D strategy:
Novel molecules: In-house discovery of new chemical entities
Licensing: Acquire rights to promising compounds from international partners
Formulation development: Novel delivery systems for existing drugs
Generics: Cost-effective generic versions of off-patent drugsAcademic Collaborations
Landsteiner partners with leading Mexican research institutions:
- National Autonomous University of Mexico (UNAM): Basic neuroscience research
- Instituto Politecnico Nacional: Pharmacology and toxicology
- Universidad Nacional Autónoma de México (UNAM): Clinical research
- CINVESTAV: Drug discovery and development
International Partnerships
The company has established licensing agreements with:
- European pharmaceutical companies: Novel compound licensing
- US biotech companies: Technology access agreements
- Japanese pharmaceutical firms: Formulation partnerships
Manufacturing
Landsteiner Scientific operates GMP-certified manufacturing facilities:
- Oral solids: Tablets, capsules, granules
- Injectables: Vials, ampoules
- Topicals: Creams, ointments
Quality systems meet Mexican (COFEPRIS), US (FDA), and European (EMA) regulatory standards.
Market Position
Landsteiner Scientific is one of the leading Mexican pharmaceutical companies:
| Metric | Position |
|--------|----------|
| CNS market (Mexico) | Top 5 |
| Cardiovascular market (Mexico) | Top 10 |
| Overall pharmaceutical (Mexico) | Top 15 |
The company competes primarily with:
- Pfizer Mexico: Global innovator
- Novartis Mexico: Swiss multinational
- Sanofi Mexico: French pharmaceutical
- Bayer Mexico: German conglomerate
- Generic manufacturers: Local and regional
Regional Expansion
Landsteiner Scientific has expanded beyond Mexico:
Central America: Guatemala, El Salvador, Honduras
Caribbean: Dominican Republic, Puerto Rico
South America: Colombia, Peru (select products)The company tailors products to regional disease burden and regulatory requirements.
Regulatory Affairs
Landsteiner maintains regulatory expertise across Latin America:
- Mexico: COFEPRIS registration and compliance
- Central America: REGUMAT regulatory harmonization
- Colombia: INVIMA registration
- Brazil: ANVISA consultation (planned)
Corporate Social Responsibility
Landsteiner Scientific is committed to improving healthcare access:
Patient assistance programs: Reduced-cost medications for qualifying patients
Medical education: Training for healthcare professionals
Research support: Funding for academic research in priority areas
Community health: Screening and awareness programsLandsteiner Scientific has shown steady growth:
| Metric | 2023 | 2022 |
|--------|------|------|
| Revenue | $85M | $78M |
| R&D | $12M | $10M |
| Employees | 500 | 480 |
Revenue is generated through product sales in Mexico and regional exports.
Future Directions
Landsteiner Scientific's strategic priorities include:
Neurology expansion: Additional CNS programs in epilepsy and Alzheimer's
Biosimilar development: Entry into biologic therapies
US market entry: FDA approval pathway for select products
Innovation center: Establish R&D center in US or Europe
Digital health: Telemedicine and digital therapy platformsSee Also
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Mexican Pharmaceutical Companies](/companies/mexican-pharma-overview)
- [Cardiovascular Disease Treatments](/diseases/cardiovascular-overview)
- [Latin America Biotech](/companies/latam-biotech-overview)
References
[Landsteiner Scientific Website (2024)](https://www.landsteiner.com.mx)
[Kalia LV, Lang AE, Parkinson's disease (2015)](/[DOI:10.1016/S0140-6736(14)60193-8](https://doi.org/10.1016/S0140-6736(14)60193-8))
[Schapira AHV, et al., New pharmacological approaches to the treatment of Parkinson's disease (2019)](https://doi.org/10.1002/mds.27782)
[Rodriguez-Sanchez MI, et al., Mexican pharmaceutical industry and neurological drug development (2018)](https://doi.org/10.1016/j.health.2018.06.001)